Skip to main content
DMRA $23.22 -4.44%
DMRA logo
DMRA · Damora Therapeutics, Inc.
Track DMRA — free
$23.22 -1.08 (-4.44%) At close · Nov 20
Market Cap
$1.44B
Shares
61.90M
Volume · Nov 20 643.39K Avg daily vol (3M) 577.78K
All webcasts

Conference · 2026-11-17

Damora Therapeutics, Inc. (DMRA) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 27:58 39 turns
Period
2026-11-17
Runtime
27:58
Sources
2 artifacts

Transcript & audio

27:58 Audio
Matt Paget Analyst — UBS

Thank you guys for being here. We're going to get started with our next session. My name is Matt Paget. I'm on the research team here at UBS working with Mikey. We are excited to welcome our next presenting company, Demora Therapeutics, and we have the team here, guys. Thanks for being here. Maybe you want to give a quick introduction and then some background on Demora and the progress you made this year and kind of the MCALR. It would be great. Thanks.

Yeah, so just quickly for introductions, I'm Jen Jarrett, and I'm the CEO of DeMora.

I'm Sherwin Satarza. I'm the Chief Operating Officer.

So, background on Demora. So, we are a Fairmont company. We're actually the sixth company that was founded by Fairmont. I'm sure you guys are familiar with a lot of the other Fairmont companies. They're up to like 11 or 12. They're definitely double digits now. But we were founded specifically to focus on hematological diseases, and our initial focus is on the myeloproliferative neoplasm space. So myeloproliferative neoplasm is a group of blood cancers. The two that we are focusing on is essential thrombocytemia, which is when a patient produces too many platelets, and myelofibrosis, which is when a patient cannot produce healthy blood cells. And so these patients tend to be either anemic or neutropenic, et cetera. The specific mutation that we are focusing on is It's something called the Kallar mutation, and it is a key driver of disease in patients with those two diseases, essential thrombocytemia and myelofibrosis, and in fact, one-third of patients with those two diseases have this mutation, so it is a very prevalent mutation, and there's about 45,000 patients in the U.S. alone that have that mutation, so that translates into a TAM in the U.S. of over $10 billion. Our lead molecule is something called DMR001. It was a molecule that was created by Paragon. For those of you that don't know Paragon, Paragon is a company that's wholly owned by Fairmont. All they do is make antibodies. So for most of the Fairmont companies that you know about, Uruka, Spire, Apigee, et cetera, all of their antibodies came from this platform. And so this platform, I think, now has a very well-deserved reputation for creating best-in-class antibodies. And we believe that DMR001 is also a best-in-class antibody. So like I said, DMR001 targets the CalR mutation. So as a result, it is blocking the key underlying cause of disease in patients that have this mutation. It just entered a Phase I study a few months ago. The study is now open in Australia and the U.S. We're going to open in several other countries over the next few months. And it's going to be a very big Phase 1, 1B study from a site perspective. And our goal, obviously, is to get the Phase 1 enrolled as quickly as possible and to be able to start a Phase 3 by the middle of 2028. So we're very excited about what we're doing. We have a lot of questions, I know, that are teed up specifically about DMR-001, so I'll stop there.

Matt Paget Analyst — UBS

Yeah, absolutely. It's a really exciting space. Obviously, we just saw an acquisition yesterday from another MCALR program, so there's a lot of investor enthusiasm. In the space. I wanted to ask if you could talk a little bit about what we've seen so far from MCALR-directed drugs that kind of validates this as a target across different indications, and, yeah, we can go from there. Yeah.

So stepping back in time, in ASH 2022, which was when the first presentation was made at a major medical meeting on this target, and at that meeting, Insight presented preclinical data for their antibody that targets the Keller mutation. This was an oral presentation to a packed audience, and it was the first time that a preclinical data presentation got an oral at ASH. So it made a huge splash, and what they showed there was obviously just preclinical data validating this pathway and the fact that this is, like, a very important pathway with a very large percentage of patients with MPNs. And then in 2025 was when they presented their first initial clinical data at EHA. Stepping back to ASH, it was when Paragon saw that preclinical data at ASH that they recognized the two major liabilities with 989. First was that it had a very suboptimal PK profile, which resulted in a very short half-life. That's why that drug needs to be given every two weeks by IV administration. The second major liability that they identified was that while their drug bound well to the type 1 mutation, which is one of the types of mutations with patients that have mutant CalR, it did not bind nearly as well to the type 2 mutation. And that has played out in the clinic. And so going back to the data that was presented at EHA in 2025, this was the first data set that was presented in essential thromocytemia. And the data looked very, very good in type 1 patients, but much less active in patients with type 2 disease. So exactly what you expected to see based on the preclinical data. That said, there was so much excitement around this data presentation that Insight actually experienced a $8 billion increase in market cap just based on this data presentation at EHA in the middle of 2025, which just shows how much potential people saw in this class of therapies. What they're now showing is about an 80% response rate in type 1 patients with ET, but only about a 50% response rate in patients with type 2 disease. In myelofibrosis, they're seeing a similar pattern where they're seeing about half the response rates in patients with a type 2 mutation relative to patients with a type 1 mutation. And then, as I mentioned earlier, they're also having to administer their drug every two weeks by IV administration, and we have a much better form of administration. So the inside data is what has convinced everybody that this is a very validated and a very effective pathway. The other thing that they've shown is this is a very well-tolerated mechanism. Patients are staying on drug for very long periods of time. In the case of the ET data set in particular, they're really seeing no AEs that stand out. So that's another thing that people really like about this class of therapies. But that is the data set that, like I said, has convinced everybody that this is a very promising class of therapies for the treatment of these diseases.

Perfect.

Matt Paget Analyst — UBS

Yeah, so you guys are in phase one now. I want to talk about the phase one study and design, eventually what you're going to show mid-year, next year. But first, could you just talk about the design of your drug, how it's different from the InSite molecule, and what you've done to kind of make this an optimal MCLR-directed therapy?

Yeah, so as I mentioned, when Paragon saw this preclinical data in 2022, that was when they started work on our drug DMR001. And the two main things that they were solving for is a better PK profile and longer half-life, and then much better activity against the type 2 mutation. And it actually took them three years to get to what is now DMR001. And the big challenge was significantly dialing up the type 2 activity while retaining activity against the type 1 mutation. And so we think for anybody that's coming from behind, they are going to have the same challenge. And so Paragon, you know, one of the best antibody development companies in the world, still took them three years to get to a really good molecule against this mutation, which I think tells you how difficult it is to develop a good drug against this mutation. So in terms of the two major benefits that our drug has as a result of all the work that Paragon did is our drug can be administered every four weeks subcutaneously. And actually, we're starting in the clinic day one. Within every four-week subcutaneous administration, we'll ultimately develop this drug in an auto-injector pen, some very similar technology that you're used to from the GLP-1s and autoimmune disease drugs. And the other major benefit of our drug is that it, pre-clinically, has much better activity against the type 2 mutation. And we expect that to play out in the clinic as well. For those that of you are wondering how big is that type 2 mutation patient population, If you look at the patients that were enrolled in the INSIGHT study so far, it's about 55% of the ET patients and about 40% of the MF patients. So it's a very, very large patient population, and obviously it's... It's much more optimal to have a drug that treats all patients versus only works well in type 1 or only works well in type 2. So we think the major advantage of our drug is that it's pan-mutant, and the goal of this drug is to work equally well in type 2 as in type 1.

Matt Paget Analyst — UBS

And you guys have some data coming up at ASH, actually, where I think you're showing this. Not just type 1, type 2, but even there are some smaller subsets of mutations, too, where you think you're active, too. Can you just talk about maybe the poster presentation, and you'll have ASH coming up?

Yeah, so we have some data that's coming up in a poster. And there we are showing the activity of DMR001 versus a reference antibody, which we believe is Insights 989. So since Insights patent is published for 989, we can basically synthesize their molecule. So we've done a head-to-head comparison preclinically in what we've shown in 10 different mutations. So it includes type 1 and type 2, as well as eight different mutations that fall between type 1 and type 2, that our drug is much more active relative to 99. So we did three different experiments against every mutation. So we didn't want to just do one experiment. Sometimes you can get, like, an outlier of a result, but here we did three for every single mutation, and you'll see in that posture the increase in potency that we got across those mutations. We've already disclosed that the average was 95 times, which is obviously like a very significant improvement in potency, and we think that that demonstrates very clearly that this is a drug that clearly has much better pan-moon activity relative to what we think 989 has.

Matt Paget Analyst — UBS

Perfect. So phase one study is underway now. Could you just talk about the design? And we've talked a little bit about what you're hoping to do with the design to get to kind of find the optimal dose going across ET and MF. So talk about the design, what we'll be able to show when we have data mid-year, yeah.

Yeah, so why don't I turn it over to Sean?

Yeah, so it's a phase one, phase one B study that's open now in Australia and in the U.S. and will be, as Jen mentioned, opening the study in a number of other countries over the next few months. It's set up to move quickly through dose escalation, and so we can get to expansion cohorts and build out a data set more broadly. And we've done this in a few different ways where the Bayesian study design allows you to, as you dose escalate and clear dose levels, Enrich lower-dose-level cohorts with the broader patient population, so, again, allowing to move quickly and broadly at the same time. It includes ET and MF patients together in dose escalation. We were able to get a 100-milligram starting dose every four weeks up Q, which is a significantly higher starting dose than what Inca99 was able to do as the first program in this class to go through regulatory reviews, and that 100-milligram is projected to be within the therapeutic range, so we don't expect to need too many dose levels to get through dose escalation before we can expand. And once we identify a dose and are able to put it into expansions, we can have, you know, several expansions running at the same time, looking at specifically ET, MF, different subtypes of patients as well.

Matt Paget Analyst — UBS

Yeah. Can you talk a little bit about the subtypes you're going to take a look at across ET and MF, you know, treatment experience, treatment naive, maybe an MF monotherapy versus combos with Jackify? I, you know, what could you have? What could you help to show? And then maybe we can talk to you about kind of what would be a good result from that data.

Sure. The patient population initially coming into the study during dose escalation will be ones that have had at least one prior therapy or are intolerant and eligible for standard of care therapy. So it's going to include a patient population that is, you know, quite varied going into the expansions as well. As we kind of look at the data set sort of evolving over time, right, it's a dose escalation portion of the study. When we look to present the data initially next year, it will be from the early part of the study, and we're going to want to look at sort of across the populations that we've been looking at. When you look at the sort of cadence with which these patients demonstrate benefit or clinical response, The ET population certainly has an earlier readout than what the MF patients that require, you know, 12 weeks or so to get a scan and demonstrate that spleen volume reduction. So, you know, the early signals we want to see is the translation of our preclinical profile into clinical activity, pan-mutant activity, seeing the translation of some of the PK data into what we'll see in the clinic with a longer half-life, less frequent dosing.

Matt Paget Analyst — UBS

So maybe just on the ET side first, I mean, you mentioned some of what insight has shown in ET. Do you think it would be fair to kind of benchmark against that insight data and especially on the type 2 side to show that we really are looking at pan mutant activity? And then from there, to what extent can we extrapolate that forward to MF and those populations as well?

What's nice is, you know, the bars in ET are relative, I'm sorry, for type 2 disease, both in ET and MF are relatively low. And so what they showed, again, in ET is that in type 2 patients at their highest dose, they were getting to a 50% hematological response rate. And that actually included like an incomplete response. So that feels like, you know, the bar from an ET perspective. And then MF, it's even a lower bar. And so in JAK, inexperienced patients in type 2, they were seeing about a 30% SVR, 35. And then at the other end of the spectrum, in type 2 patients that had prior JAK, they were seeing only a 5% response rate. So again, what's nice about those is those are pretty low bars. And obviously, the lower the bar, I think the faster it is to be able to show an improvement over what they've shown in their clinical data.

Matt Paget Analyst — UBS

I wanted to take a step back just for a second, focus on ET, and then maybe we can talk about MF. But just on ET, I think people don't know this area as well as MF. Could you just talk about? How is this treated normally and, you know, what the opportunity is, what this market could look like for you guys?

Yeah. So really stepping back, you know, so ET, as you said, I think is less well-known. These are patients that have very, very high platelet counts or they have platelets that just don't function well. So as a result, these patients are at very high risk of either thrombotic events or bleeding events because these platelets aren't always functioning like they should. On top of that, because you have these high-level platelets, they have a whole range of really serious symptoms, so very bad migraines, a lot of fatigue, a lot of pain, tingling in their hands and feet. So the more we learn about ET, I think the more we appreciate that the symptom burden that these patients experience is really high. On top of that, these patients have a fairly high risk of transforming to myelofibrosis. And for patients with the CalR mutation, their risk of transforming to myelofibrosis is actually much higher than patients with other mutations. So for a lot of patients, that's almost what they fear the most and what really drives their desire to get treatment is something that slows the progression of their disease and prevents them from progressing to myelofibrosis. And once you have myelofibrosis, that's when your overall survival becomes significantly shortened. So one of the reasons why there's so much interest in this class of therapies is because people believe that this is a disease-modifying class of therapy and should reduce the likelihood of progressing to myelofibrosis. The current treatment option today that most patients get is hydrea, which is basically a chemotherapeutic agent. So all that does is, you know, basically kills all your blood cells. So while it does bring your platelet levels down, it obviously does nothing as far as really modifying the course of disease or slowing the progression of the disease to myelofibrosis. So that is why there's so much interest in this class of therapies, not just in the clinician community, but that we've been surprised on how well-educated the patient community is on this class of therapy and how motivated they are to get into a clinical study for a mutant killer drug. And we hear all the time from sites that they have waiting lists for patients that want to get on a study for this class of therapies, which is obviously great for us as we're now enrolling our clinical study.

Matt Paget Analyst — UBS

So a significant population here treated with hydrea, basically chemotherapy for their disease. This would be kind of a disease-modifying therapy. Should we think about this as like a chronic therapy, or is it more you go into a remission? Like, talk about the framework there. Maybe that's why the subcutaneous profile matters, and just talk about kind of how that plays into this.

Yeah, so this is a disease. Once you're diagnosed, you will have this disease for life, and it's progressive over time. So, you know, your disease is never going to get better. It may stay the same, but, you know, generally, it will get worse over the course of your life. So as a result, particularly for each of these patients who still live for, like, 20, 25 years, convenience is very, very important. And so right now, 989 is being administered every two weeks as an IV infusion. So patients are having to come into the infusion clinic to get treated there. So having an every four-week subcutaneous option that can be done at home, obviously, would be very, very advantageous. And we hear all the time, you know, these patients live, like, hours away from the clinic. Like, it's really difficult for them to come into the clinic every two weeks. So again, I think it just speaks to the attractiveness of having a much more convenient option that patients can take at home, particularly given this is a chronic disease. And these patients are seeing their clinician probably only three months typically. So for them to have to go in every two weeks to an infusion center is a major inconvenience for them.

Matt Paget Analyst — UBS

Yeah. And then shifting gears to myelofibrosis, there is a standard of care. There are already JAK inhibitors. Um, we talked a bit about kind of like what you would maybe hope to show in second line. I mean, maybe just talk again in second line and then in frontline patients, and then you have monotherapy and you have combination. How should we think about comparing to Jackify to the new Insight 989, which is their MCALR, and, like, how to think about that MF data?

Yeah. Maybe to start, one thing is that the current treatment options, Jackify, Momolotinib, et cetera, Jackify specifically works less effectively on mutant KALR patients than it does in patients with the JAK2 mutation. So we know, just even from Jackify's EU label, that the response rate for spleen volume reduction in non-Jack mutated patients is about half of that with the other patients. So, again, a high urgency to treat patients that have this particular mutation with a disease-modifying agent. So we've seen from Jack inhibitors as well, they don't really have the same effect on reducing the molecular burden of the disease. It's really just directed at spleen volume reduction, symptom improvement. And for the first time, this class of mutant CalR drugs is able to perhaps change the course of their disease. And when you think about that in the context of patients who have maybe even milder myelofibrosis, the intermediate low-risk population, that are really just a watch and wait right now, that's a pretty tough position for a patient to be in, that they're not sick enough to get treatment, and your disease needs to progress to a place where the only treatment option you do have is still not going to ultimately change the course of your disease. And so with this class of drugs, we have an opportunity to do that differently. The current sort of demonstration of benefit that we have from Newton-Calihara is with Inca-989, where they've shown nice reductions in spleen volume, primarily in the frontline population. Their JAK-ineligible population has a really nice response rate. Again, you see that differential in the type 1 versus the non-type 1 patients, as Jen was mentioning, particularly in the relapsed refractory myelofibrosis patients, where you have a very low response rate in the non-type 1 patients. So, again, the opportunity here with the pan-mutant activity of OO1 is the opportunity to bring a better level of care, better level of outcomes for both patient populations.

Matt Paget Analyst — UBS

Maybe, like, philosophically, do you feel like you need to combine with a JAK inhibitor, given that you're kind of going after the underlying driver mutation here already?

Yeah, no. I mean, the idea there is that if you have an agent that can treat the underlying cause of the disease, the addition of that sort of more symptom-directed therapy would not be necessary there. Now, I think one of the things we're learning and continue to learn with more data coming at ASH with Inca-989 is, you know, the responses deepen over time, right? And so we'll be interested to see how that plays out, particularly on the TSS endpoint. Is there some improvement over time? And the question still remains, what is the additive benefit of combining with ruxolitinib versus not? I think the advantage we have is we can look at not just ruxolitinib, we can look at potential other agents to combine with as well, if there is that additive advantage, which, again, shouldn't need to be there if you have a really good mutant CalR-directed antibody.

Matt Paget Analyst — UBS

So maybe, I think what I heard you say was maybe there's benefit on not just SVR, but particularly on TSS, which is the symptom score in myelofibrosis 2, combining with either a JAK or another type of agent. Is that kind of how you guys are thinking about it right now?

As the data matures, I think that'll help our thinking around that. I think we also need to be mindful of the disease-modifying endpoints or measurements that we can have with this agent as well, with improvements in amemia, improvements with blast counts, improvements with VAF. So these are all things that we're going to be looking at to see if those deepen over time with these therapies.

Matt Paget Analyst — UBS

Insight will have some what I think we call true frontline data instead of pseudo-frontline jack-ineligible at ASH this year. Is there anything that you guys are looking for as you look across that data to validate or tell you about the opportunity here for your drug and MCALR?

I think the main thing is, are they going to go with a combination versus monotherapy, and their phase three in the frontline setting will be the main thing. And they've... And, you know, depending on when they've spoken, they've indicated one or both or just doing like a three-arm study, which I think for them would be time-consuming and a much bigger study. So, you know, we'll see what the data shows and whether they feel comfortable enough going with a monotherapy strategy. And, again, you know, the big issue is just that lack of activity in type 2 patients, which then dilutes the activity across the broader patient population in their study. So I think that for them is their issue in going with a monotherapy strategy. The other thing that we're interested in seeing that they've been talking about is it sounds like they're getting deepening responses over time, which is like what we would expect with this class of therapies, and obviously it's like good for everybody. So that's another piece of their data that we're very interested in seeing.

Matt Paget Analyst — UBS

Um, maybe just stepping back broadly in terms of the competitive landscape, there are others kind of working in the space. There are other MCLRs. One was acquired yesterday. There are other people working, including Lily, working on, like, a broader Jack-type targeted approach. Can you just talk about where you feel you're positioned in the competitive landscape relative to the other players? There's also a J&J by-specific. We can maybe talk about that approach, too. But just how do you feel about your lead drug here?

So we have the most advanced half-life extended pan-mutant, mutant-color antibody in the clinic, you know, period. So anything else that's pan-mutant is behind us. Calatrix, which was a company that was acquired yesterday by Lilly, we think they're at least 12 months behind us. You know, we'll see, like, if Lilly does some more work with their antibody, which could slow them down even more. So we do think that they're materially behind us. We're also not sure, like, you know, if they have anything better than what we have, particularly on the type 1 side. You know, it does seem like their activity against type 2 will be similar to ours, but based on the own experiments that we have done, it's not clear that their type 1 activity is as good as ours. And then you mentioned Insights Next Gen drug, that is also behind us, so we think that's at least six months behind us, maybe more than that. And what's also important to note is that we have another antibody that's about to go into the clinic, which is DMR002, which is an FC-enabled mutant killer antibody. So that molecule will be in the clinic either before Insights Next Gen molecule and, you know, certainly before the Calatrix molecule. So we'll have two mutant killer antibodies before Insights Next Gen, and then, you know, you look at Calatrix, and they're now, you know, sort of third, fourth, or fifth. You know, I'm not sure where in the clinic, and we do have some time advantage.

Matt Paget Analyst — UBS

So I wanted to ask you about the second and third programs in your pipelines. You have basically three different ways to target CalR in your pipeline. It's a whole portfolio, basically. How should investors think about the second and the third programs, the kind of like the patient segments that maybe those would be a good fit for or if those are?

Yeah, so just rewinding for a second, the reason we have three antibodies is because in that first data disclosure in the preclinical abstract presentation in 2022, it wasn't clear if an FC-null approach was going to work. And so Paragon set out to develop the FC-enhanced antibody, DMR-002, as well as a T-cell engager program. So fast forward to today, we know that the FCNL approach, particularly one that's going to have activity across the type 1 and non-type 1 patients, should be the backbone of lifelong therapy for these patients. Now, there may be some patients who need a little bit more firepower because their disease is more advanced, for example. And that's where the DMR-OO2 program is really nicely situated to be in the clinic at the same time, where we can start to enroll patients that start to look at sort of where the activity of OO1 makes sense, where the activity of OO2 makes sense, and learn from those two programs to tailor them accordingly. I mean, OO1 is our lead horse. We think that's going to treat the vast majority of patients, but if there are some sicker patients that need some immune activation that OO2 brings, we'll have that opportunity to test that as well. OO3 is our T-cell engager. You asked a question earlier about J&J's data. You know, we were all waiting to see what exactly that looked like. As expected, you see the safety profile, 40% CRS rates, about 50% grade 3 adverse events. You're not seeing the response rate that, you know, perhaps we were expecting. In this late-lying ET population, we'll see what their MF data looks like, but I think it's a nice opportunity we have to learn from that and engineer our TCE to fill any gaps that they may have. The interesting challenge is, you know, how much more can you get out of a TCE that you won't get out of an FCNOL or an FC-enhanced approach?

Matt Paget Analyst — UBS

So the FC-enhanced entering the clinic, I think, this year, what are the timelines for the T-cell engager? It sounds like there may be even opportunities to tweak that, as you learn from J&J, basically. What are the timelines for that program?

We've guided towards a regulatory submission next year for the TCE program.

Matt Paget Analyst — UBS

Perfect. And just to put a finer point on it, you think that those two programs are maybe more for, like, refractory myelofibrosis? Is that kind of the right way to think about it?

I would say yes for the TCE. I think the OO2 program will see what the safety profile is. No one else has tested an FC-enhanced antibody in this population. And so depending on what that profile looks like, we can see how far that goes into which patient populations that go.

Matt Paget Analyst — UBS

It's a good place to leave it. Exciting year ahead for Demora. First key data mid-year next year. So, guys, thank you so much for being here.

Analyst Q&A · 1 question
Full-screen source Call document